中国病理生理杂志2024,Vol.40Issue(6):1070-1077,8.DOI:10.3969/j.issn.1000-4718.2024.06.013
贝母素乙通过下调CDK2/CDK4/CDK6和cyclin D1表达抑制人结肠腺癌SW480细胞活力
Peiminine inhibits viability of human colonic adenocarcinoma SW480 cells by down-regulating expression of CDK2/CDK4/CDK6 and cyclin D1
摘要
Abstract
AIM:This study examined the inhibitory effect of peiminine on the human colonic adenocarcino-ma cell line SW480 and explored the underlying mechanisms.METHODS:SW480 and human normal colonic epithelial CCD-841CoN cells were treated with different concentrations of peiminine and subjected to the CCK-8 assay to select the optimal treatment time and concentration of the compound.SW480 cell migration and invasion were evaluated by the wound-healing and Transwell assays.Cell cycle progression was analyzed by flow cytometry.The expression levels of cell cycle-related proteins were examined by Western blot.SW480 xenograft tumor model was established in nude mice to ex-amine the effect of peiminine on tumor growth and the expression of cell cycle-related proteins in vivo.RESULTS:Peimi-nine(110 mg/L)significantly inhibited the proliferation of SW480 cells compared with the control group(P<0.01),caused cell cycle arrest at G1 phase,and significantly downregulated the expression of cyclin dependent kinase 2(CDK2),CDK4,CDK6,cyclin D1,p-Rb/Rb,E2F1,E2F3,and E2F4(P<0.05).Peiminine inhibited SW480 xenograft tumor growth,prolonged the survival of model mice,and affected the expression of CDK2,CDK4,CDK6,and cyclin D1 in tu-mor tissues.CONCLUSION:Peiminine promotes G1 phase arrest by down-regulating the expression of CDK2,CDK4,CDK6,and cyclin D1,thereby inhibiting the proliferation of SW480 cells.关键词
SW480细胞/贝母素乙/周期蛋白依赖性激酶/细胞周期Key words
SW480 cells/peiminine/cyclin-dependent kinases/cell cycle分类
医药卫生引用本文复制引用
杨霞,朱羿龙,金宁一,李雅茹,李玥,毛泓月,白冰,李一权,韩继成,万怡宁,谢诗敏..贝母素乙通过下调CDK2/CDK4/CDK6和cyclin D1表达抑制人结肠腺癌SW480细胞活力[J].中国病理生理杂志,2024,40(6):1070-1077,8.基金项目
吉林省自然科学基金资助项目(No.YDZJ202401687ZYT) (No.YDZJ202401687ZYT)
吉林省中医药科技项目(No.2024255) (No.2024255)
吉林省科技发展计划项目(No.20220508075RC) (No.20220508075RC)